Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + Bevacizumab + RALOX-HAIC in HCC with VP3/4 PVTT
NCT07327788Phase 2Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in hepatocellular carcinoma (HCC), sponsored by Nanfang Hospital, Southern Medical University. Started Dec 2025; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07327788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07327788.